Allergan (AGN) Rating Restated
In a note sent to investors and clients on Wednesday morning, Allergan (AGN) Stock had its Outperform Rating restate by equity analysts at Leerink Partners. They currently have a $242.0 PT on company. Leerink Partners’s target suggests a potential upside of 42.03 % from the company’s current price.
AGN is now trading 0.00% lower at $0.00 as of 4:05 PM New York time. Allergan’s stock is 0% over the past 200 days. It has underperformed the S&P 500 Index, which has added 6.00% over the same time period.
According to data compiled by Thomson Reuters, Allergan (AGN)’s stock is covered by 16 equity analysts across the Street, with 0 analysts giving it a Sell rating, 18 a Buy rating, while 2 consider it a Hold. The 12-month consensus target price for the stock is $293.75, which reflects an upside potential of ∞% over the current price.
Mengis Capital Management Inc. had the most significant stake with ownership of 6,470 shares as of Q2 2015 for 1.24% of the US equity exposure. Peddock Capital Advisors Llc is another very bullish active investment manager who is owning 6,483 shares of Allergan or 0.92% of their US equity exposure. Moreover, Mitchell Mcleod Pugh & Williams Inc have 0.8% of their US equity exposure invested in the company for 3,975 shares. The New York-based fund Norman Fields Gottscho Capital Management Llc disclosed it had acquired a stake worth about 0.28% of the active investment manager’s stock portfolio in Allergan. The California-based fund Grassi Investment Management is also positive about the stock, possessing 1,825 shares or 0.27% of their US equity exposure.
Allergan (AGN) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of shares. Allergan has a 52 week low of $0.00 and a 52 week high of $0. The company has a market cap of $ and a P/E ratio of 0.
Get the latest Allergan (AGN) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Leerink Partners Maintains a Outperform Rating on Allergan (AGN) and $242.0 Target appeared first on Octafinance.